Statins and Inflammation
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023001%3A_____%2F21%3A00081787" target="_blank" >RIV/00023001:_____/21:00081787 - isvavai.cz</a>
Nalezeny alternativní kódy
RIV/00216208:11110/21:10434704 RIV/00064165:_____/21:10434704
Výsledek na webu
<a href="https://link.springer.com/content/pdf/10.1007/s11883-021-00977-6.pdf" target="_blank" >https://link.springer.com/content/pdf/10.1007/s11883-021-00977-6.pdf</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1007/s11883-021-00977-6" target="_blank" >10.1007/s11883-021-00977-6</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
Statins and Inflammation
Popis výsledku v původním jazyce
Purpose of Review Chronic inflammation has been recognized as one of the most important pathophysiological mechanisms' initiation and progression of atherosclerosis. Statins belong to most successful therapeutic agents in the prevention and treatment of atherothrombotic vascular disease. Their non-lipid related effects including suppression of inflammation have been repeatedly proven in both experimental and clinical settings. Recent Findings Recently, the importance of inflammation in the process of atherosclerosis has been confirmed by interventions targeting inflammation selectively. Clinical trial with selective inhibitor of a principal inflammatory mediator interleukin 1-beta - canakinumab - confirmed the notion of direct vasculoprotective effects of primarily targeting inflammation. This has increased interest in the non-lipid, pleiotropic and, particularly, anti-inflammatory effects of statins. Summary Anti-inflammatory effects of statins have been proven both experimentally and in clinical settings beyond any doubt. They comprise a direct positive effect on not only many cell types and pathways that are lipid independent but, also, some that are mediated by lipid modification. Undoubtedly, suppression of inflammatory response by statins contributes to their generally positive action in atherosclerosis and represents an important part of the vasculo- and atheroprotective effect of this drug class.
Název v anglickém jazyce
Statins and Inflammation
Popis výsledku anglicky
Purpose of Review Chronic inflammation has been recognized as one of the most important pathophysiological mechanisms' initiation and progression of atherosclerosis. Statins belong to most successful therapeutic agents in the prevention and treatment of atherothrombotic vascular disease. Their non-lipid related effects including suppression of inflammation have been repeatedly proven in both experimental and clinical settings. Recent Findings Recently, the importance of inflammation in the process of atherosclerosis has been confirmed by interventions targeting inflammation selectively. Clinical trial with selective inhibitor of a principal inflammatory mediator interleukin 1-beta - canakinumab - confirmed the notion of direct vasculoprotective effects of primarily targeting inflammation. This has increased interest in the non-lipid, pleiotropic and, particularly, anti-inflammatory effects of statins. Summary Anti-inflammatory effects of statins have been proven both experimentally and in clinical settings beyond any doubt. They comprise a direct positive effect on not only many cell types and pathways that are lipid independent but, also, some that are mediated by lipid modification. Undoubtedly, suppression of inflammatory response by statins contributes to their generally positive action in atherosclerosis and represents an important part of the vasculo- and atheroprotective effect of this drug class.
Klasifikace
Druh
J<sub>imp</sub> - Článek v periodiku v databázi Web of Science
CEP obor
—
OECD FORD obor
30201 - Cardiac and Cardiovascular systems
Návaznosti výsledku
Projekt
<a href="/cs/project/NU21-01-00146" target="_blank" >NU21-01-00146: Analýza volných DNA a miRNA jako markerů svalového poškození u pacientů léčených statiny</a><br>
Návaznosti
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Ostatní
Rok uplatnění
2021
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
Current atherosclerosis reports
ISSN
1523-3804
e-ISSN
—
Svazek periodika
23
Číslo periodika v rámci svazku
12
Stát vydavatele periodika
NL - Nizozemsko
Počet stran výsledku
8
Strana od-do
"art. no. 80"
Kód UT WoS článku
000724753700001
EID výsledku v databázi Scopus
2-s2.0-85120355548